[go: up one dir, main page]

MX9705077A - Agente para la profilaxis y tratamiento del trastorno de la funcion visual. - Google Patents

Agente para la profilaxis y tratamiento del trastorno de la funcion visual.

Info

Publication number
MX9705077A
MX9705077A MX9705077A MX9705077A MX9705077A MX 9705077 A MX9705077 A MX 9705077A MX 9705077 A MX9705077 A MX 9705077A MX 9705077 A MX9705077 A MX 9705077A MX 9705077 A MX9705077 A MX 9705077A
Authority
MX
Mexico
Prior art keywords
asthenopia
agent
prophylaxis
treatment
formula
Prior art date
Application number
MX9705077A
Other languages
English (en)
Other versions
MXPA97005077A (es
Inventor
Toshiharu Tsuboi
Noriko Watanabe
Original Assignee
Takeda Chemical Industries Ltd
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Senju Pharma Co filed Critical Takeda Chemical Industries Ltd
Publication of MX9705077A publication Critical patent/MX9705077A/es
Publication of MXPA97005077A publication Critical patent/MXPA97005077A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un agente para la profilaxis y tratamiento de trastorno de la funcion visual, que comprende un compuesto de la formula [1]: en donde el anillo A es opcionalmente substituido, R1 es un hidrogeno o un amino opcionalmente protegido, y R2 es un grupo capaz de liberar un proton, o una sal del mismo; el agente para la profilaxis y tratamiento de trastorno de la funcion visual de la presente invencion tiene efecto preventivo y terapéutico superior sobre la astenopía, y muestra supresion de alargamiento axial, supresion de degradacion de funciones retinales y accion de recuperacion de funcion retinal; por lo tanto, el agente se puede usar ventajosamente como un agente clínicamente aplicable para la profilaxis y tratamiento de trastorno de la funcion visual.
MXPA/A/1997/005077A 1996-07-05 1997-07-04 Agente para la profilaxis y tratamiento del trastorno de la funcion visual MXPA97005077A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP17693396 1996-07-05
JP8-176933/1996 1996-07-05
JP8-176933 1996-07-05
JP21394196 1996-08-13
JP8-213941/1996 1996-08-13
JP8-213941 1996-08-13
JP31403396 1996-11-25
JP8-314033 1996-11-25
JP8-314033-1996 1996-11-25

Publications (2)

Publication Number Publication Date
MX9705077A true MX9705077A (es) 1998-05-31
MXPA97005077A MXPA97005077A (es) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
ID17647A (id) 1998-01-15
KR980008226A (ko) 1998-04-30
EP0819431A1 (en) 1998-01-21
CN1172644A (zh) 1998-02-11
HU9701150D0 (en) 1997-09-29
CA2209581A1 (en) 1998-01-05
HUP9701150A2 (hu) 1999-02-01
BR9703874A (pt) 1998-09-01
US5952338A (en) 1999-09-14
AU2843397A (en) 1998-01-15

Similar Documents

Publication Publication Date Title
MX9800411A (es) Compuestos quimicos.
AU4950993A (en) Combination of germicidal agents
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
TW369536B (en) Phosphonate nucleotide compounds
GB9514473D0 (en) Chemical compounds
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
CA2154572A1 (fr) Application du riluzole dans le traitement du neuro-sida
AU2001266575A1 (en) Chemical compounds
GB9107827D0 (en) New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU1367497A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma
MX9708452A (es) Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma.
NO983178L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
ES8401067A1 (es) Procedimiento analogo para preparar un derivado de tropil benzoato.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MY124078A (en) Eletriptan hydrobromide monohydrate
DE3476847D1 (en) A remedial or prophylactic agent for the treatment of seizures
UA41880C2 (uk) Серотонінергічні похідні ерголіну і фармацевтична композиція
MX9705077A (es) Agente para la profilaxis y tratamiento del trastorno de la funcion visual.
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
HUT75529A (en) Use of dimeticone for treating constipation
AU4944899A (en) New pharmaceutically active compounds
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.